Analysts predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will report $1.68 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the highest sales estimate coming in at $2.20 million and the lowest estimate coming in at $1.18 million. Abeona Therapeutics posted sales of $220,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 663.6%. The company is scheduled to issue its next earnings results on Wednesday, November 21st.

According to Zacks, analysts expect that Abeona Therapeutics will report full-year sales of $6.08 million for the current fiscal year, with estimates ranging from $5.63 million to $6.83 million. For the next financial year, analysts expect that the company will post sales of $18.32 million, with estimates ranging from $4.23 million to $43.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%.

A number of analysts have recently commented on the company. BidaskClub cut Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday. Maxim Group restated a “buy” rating and issued a $26.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 5th. Cantor Fitzgerald restated a “buy” rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 5th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. Finally, Mizuho assumed coverage on Abeona Therapeutics in a research report on Thursday, October 11th. They issued a “buy” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.90.

Shares of Abeona Therapeutics stock traded down $0.52 on Friday, reaching $9.36. The company’s stock had a trading volume of 591,945 shares, compared to its average volume of 657,835. The stock has a market capitalization of $419.98 million, a PE ratio of -14.18 and a beta of 1.77. Abeona Therapeutics has a 52-week low of $8.52 and a 52-week high of $22.00.

Large investors have recently modified their holdings of the company. Fortaleza Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter worth approximately $104,000. Parkside Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $160,000. United Services Automobile Association acquired a new stake in shares of Abeona Therapeutics in the second quarter worth approximately $162,000. Trexquant Investment LP acquired a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $163,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $235,000. 76.38% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.